Clin Exp Vaccine Res.  2013 Jul;2(2):71-73. 10.7774/cevr.2013.2.2.71.

Toward a universal influenza vaccine: from the perspective of protective efficacy

• Jang YH
• Seong BL

• KMID: 2167714
• DOI: http://doi.org/10.7774/cevr.2013.2.2.71

Abstract

No abstract available.

MeSH Terms

Collodion
Influenza, Human
Collodion

Reference

1. Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature. 2009; 459:931–939.

2. Ekiert DC, Bhabha G, Elsliger MA, et al. Antibody recognition of a highly conserved influenza virus epitope. Science. 2009; 324:246–251.

3. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med. 1999; 5:1157–1163.

4. Wang TT, Tan GS, Hai R, et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A. 2010; 107:18979–18984.

5. Corti D, Voss J, Gamblin SJ, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011; 333:850–856.

6. Sommerfelt MA. T-cell-mediated and humoral approaches to universal influenza vaccines. Expert Rev Vaccines. 2011; 10:1359–1361.

7. Wrammert J, Koutsonanos D, Li GM, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med. 2011; 208:181–193.

8. Jang YH, Byun YH, Lee YJ, Lee YH, Lee KH, Seong BL. Cold-adapted pandemic 2009 H1N1 influenza virus live vaccine elicits cross-reactive immune responses against seasonal and H5 influenza A viruses. J Virol. 2012; 86:5953–5958.

9. Lee KH, Seo SU, Song JM, Lee CM, Kim HA, Seong BL. Characterization of live influenza vaccine donor strain derived from cold-adaptation of X-31 virus. Vaccine. 2006; 24:1966–1974.